Haloperidol disrupts lipid rafts and impairs insulin signaling in SH-SY5Y cells.

Abstract:

:Haloperidol exerts its therapeutic effects basically by acting on dopamine receptors. We previously reported that haloperidol inhibits cholesterol biosynthesis in cultured cells. In the present work we investigated its effects on lipid-raft composition and functionality. In both neuroblastoma SH-SY5Y and promyelocytic HL-60 human cell lines, haloperidol inhibited cholesterol biosynthesis resulting in a decrease of the cell cholesterol content and the accumulation of different sterol intermediates (7-dehydrocholesterol, zymostenol and cholesta-8,14-dien-3beta-ol) depending on the dose of the drug. As a consequence, the cholesterol content in lipid rafts was greatly reduced, and several pre-cholesterol sterols, particularly cholesta-8,14-dien-3beta-ol, were incorporated into the cell membrane. This was accompanied by the disruption of lipid rafts, with redistribution of flotillin-1 and Fyn and the impairment of insulin-Akt signaling. Supplementing the medium with free cholesterol abrogated the effects of haloperidol on lipid-raft composition and functionality. LDL (low-density lipoprotein), a physiological vehicle of cholesterol in plasma, was much less effective in preventing the effects of haloperidol, which is attributed to the drug's inhibition of intracellular vesicular trafficking. These effects on cellular cholesterol homeostasis that ultimately result in the alteration of lipid-raft-dependent insulin signaling action may underlie some of the metabolic effects of this widely used antipsychotic.

journal_name

Neuroscience

journal_title

Neuroscience

authors

Sánchez-Wandelmer J,Dávalos A,de la Peña G,Cano S,Giera M,Canfrán-Duque A,Bracher F,Martín-Hidalgo A,Fernández-Hernando C,Lasunción MA,Busto R

doi

10.1016/j.neuroscience.2010.01.051

subject

Has Abstract

pub_date

2010-04-28 00:00:00

pages

143-53

issue

1

eissn

0306-4522

issn

1873-7544

pii

S0306-4522(10)00143-0

journal_volume

167

pub_type

杂志文章